Considering treatment options for your pulmonary arterial
hypertension (PAH) patients?
REVATIO® (sildenafil)—
is now available as an
oral suspension treatment
for PAH
Important Safety Information
REVATIO is contraindicated in patients with concomitant use of organic
nitrates in any form, either regularly or intermittently, because of the
greater risk of hypotension.
REVATIO is contraindicated in patients with concomitant use of riociguat,
a soluble guanylate cyclase (sGC) stimulator medication. PDE5 inhibitors,
including sildenafil, may potentiate the hypotensive effects of riociguat.
REVATIO is contraindicated in patients with a known hypersensitivity to
sildenafil or any other ingredient in REVATIO. Hypersensitivity, including
anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction has
been reported in association with the use of sildenafil.
Use of REVATIO, particularly chronic use, is not recommended in children.
Before starting REVATIO, physicians should carefully consider whether
their patients with underlying conditions could be adversely affected by
the mild and transient vasodilatory effects of REVATIO on blood pressure.
Pulmonary vasodilators may significantly worsen the cardiovascular
sta